NPI: 1871592113 · DURHAM, NC 27704 · General Acute Care Hospital · NPI assigned 07/19/2005
Authorized official SMITH, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | SMITH, JOHN (VP FINANCE) |
| NPI Enumeration Date | 07/19/2005 |
Other providers sharing the same authorized official: SMITH, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 49,398 | $1.71M |
| 2019 | 37,783 | $1.56M |
| 2020 | 20,978 | $940K |
| 2021 | 28,092 | $1.23M |
| 2022 | 28,246 | $1.31M |
| 2023 | 40,288 | $2.01M |
| 2024 | 48,592 | $2.86M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19,453 | 17,043 | $4.73M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 25,130 | 23,771 | $2.81M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 13,133 | 12,353 | $2.04M |
| 80053 | Comprehensive metabolic panel | 35,683 | 31,697 | $317K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 29,784 | 26,492 | $210K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 11,817 | 9,575 | $194K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1,715 | 1,658 | $172K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4,704 | 4,396 | $101K |
| 36415 | Collection of venous blood by venipuncture | 43,833 | 39,641 | $97K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3,073 | 2,181 | $84K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1,862 | 1,310 | $84K |
| 71045 | Radiologic examination, chest; single view | 1,977 | 1,809 | $63K |
| 0002A | 999 | 912 | $56K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1,663 | 1,604 | $56K |
| 0001A | 1,035 | 932 | $52K | |
| 71046 | Radiologic examination, chest; 2 views | 2,209 | 2,092 | $40K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1,331 | 985 | $39K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 606 | 578 | $38K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1,820 | 1,676 | $35K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3,418 | 2,918 | $35K |
| 83690 | 4,125 | 3,790 | $27K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 984 | 908 | $25K |
| 87631 | 342 | 308 | $25K | |
| 84484 | 3,545 | 2,713 | $23K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1,555 | 1,478 | $22K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 41 | 37 | $22K |
| 81025 | 3,093 | 2,923 | $21K | |
| 82553 | 2,379 | 1,976 | $16K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 429 | 424 | $16K |
| J3490 | Unclassified drugs | 4,027 | 1,104 | $13K |
| 81001 | 4,532 | 4,200 | $13K | |
| 85730 | 2,654 | 2,421 | $12K | |
| 80061 | Lipid panel | 621 | 594 | $11K |
| 84702 | 1,037 | 942 | $11K | |
| 82550 | 2,498 | 2,069 | $10K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 350 | 337 | $10K |
| 85027 | 1,868 | 1,594 | $9K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 1,652 | 1,454 | $8K |
| 85610 | 2,747 | 2,516 | $8K | |
| 83655 | 335 | 329 | $7K | |
| 59025 | Fetal non-stress test | 173 | 152 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 163 | 127 | $5K |
| 0072A | 84 | 78 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | 247 | 241 | $5K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 24 | 24 | $4K |
| 83525 | 244 | 242 | $3K | |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 359 | 274 | $3K |
| 86141 | 213 | 213 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 89 | 79 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 89 | 79 | $3K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 82 | 79 | $3K |
| 0071A | 69 | 56 | $3K | |
| 83735 | 422 | 311 | $2K | |
| 0004A | 41 | 39 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 316 | 261 | $2K |
| 81003 | 615 | 580 | $1K | |
| 82043 | 175 | 175 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 172 | 160 | $1K |
| 84550 | 194 | 194 | $1K | |
| 87522 | Neg quan hep c or qual rna | 25 | 25 | $1K |
| 83880 | 39 | 36 | $955.43 | |
| 83718 | 74 | 68 | $893.19 | |
| 93990 | 34 | 27 | $814.40 | |
| 97602 | 31 | 15 | $717.94 | |
| 90870 | 26 | 12 | $698.04 | |
| 80048 | Basic metabolic panel (calcium, ionized) | 93 | 74 | $663.41 |
| 82465 | 74 | 68 | $523.16 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 271 | 251 | $508.88 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 908 | 829 | $477.70 |
| 84460 | 46 | 38 | $325.38 | |
| 86780 | 13 | 13 | $297.00 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 28 | 25 | $246.95 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 14 | 13 | $192.43 |
| 80076 | 12 | 12 | $119.88 | |
| 83550 | 27 | 24 | $111.30 | |
| 83540 | 27 | 24 | $83.31 | |
| J1644 | Injection, heparin sodium, per 1000 units | 195 | 84 | $65.48 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 283 | 255 | $65.22 |
| 82948 | 22 | 15 | $60.33 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 24 | 12 | $58.02 |
| J2704 | Injection, propofol, 10 mg | 101 | 78 | $32.87 |
| 80047 | 30 | 24 | $31.29 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 60 | 39 | $27.34 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 172 | 98 | $26.55 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 41 | 25 | $17.12 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 116 | 54 | $16.09 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 150 | 92 | $5.89 |
| 85014 | 24 | 12 | $2.95 | |
| 84132 | 29 | 14 | $2.84 | |
| 82435 | 26 | 13 | $1.81 | |
| 84295 | 26 | 13 | $1.65 | |
| 84520 | 26 | 13 | $0.94 | |
| 91300 | 2,480 | 2,220 | $0.03 |